Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.34 |
| ▸ | GLMN | Q92990 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 4/20 | 0.33 |
| ▸ | NAMPT | P43490 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6427323 | 0.93 | DPP4 (0.40) | DPP8KDM4ETDP1ALDH1A1DPP4 | |
| SCHEMBL6426277 | 0.85 | ALDH1A1 (0.43) | ALDH1A1TSHRGAA | |
| SCHEMBL6504880 | 0.85 | TSHR (0.42) | KDM4ETDP1ALDH1A1TSHREPHX2 | |
| SCHEMBL14344793 | 0.85 | TSHR (0.42) | KDM4ETDP1ALDH1A1TSHREPHX2 | |
| SCHEMBL6507788 | 0.84 | ALDH1A1 (0.39) | KDM4EALDH1A1TSHRGAA | |
| SCHEMBL6503292 | 0.83 | ALDH1A1 (0.35) | KDM4ETDP1ALDH1A1TSHREPHX2 | |
| SCHEMBL6426995 | 0.83 | SIGMAR1 (0.30) | — | |
| SCHEMBL6427367 | 0.82 | MAPT (0.37) | KDM4ETDP1ALDH1A1TSHREPHX2 | |
| SCHEMBL6429151 | 0.81 | CYP2C19 (0.41) | KDM4ETDP1ALDH1A1TSHREPHX2 | |
| SCHEMBL6427691 | 0.79 | ALDH1A1 (0.33) | ALDH1A1TSHREPHX2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
| WO-2005075471-A2 | THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | BIOVITRUM AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | DPP8 1825/4885DPP9 1066/4885GLMN 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.